Pappas Ventures
Pappas Ventures (Pappas Capital) is a Durham, NC-based life sciences venture capital firm founded in 1994 that invests in and builds innovative biotech and healthcare companies across the US, Canada, and Asia.
- Company typePrivate
- Founded1994
- HeadquartersDurham, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Pappas Ventures does
As a venture capital and fund management firm, Pappas Ventures earns revenue primarily through management fees on committed or invested capital across its specialized funds, supplemented by carried interest on realizations; specific AUM, fee rates, and revenue figures are not publicly disclosed. Industry positioning is reinforced by memberships in the National Venture Capital Association (NVCA), BIO, and the North Carolina Biotechnology Center. The firm is led by Founder, CEO and Managing General Partner Artthur M. Pappas and operates with 11-50 employees.
Pappas Ventures firmographics
Firmographics- Name
- Pappas Ventures
- Legal name
- Pappas Capital, LLC
- Website
- https://pappasventures.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pappas Ventures (Pappas Capital) is a Durham, NC-based life sciences venture capital firm founded in 1994 that invests in and builds innovative biotech and healthcare companies across the US, Canada, and Asia.
- Ownership category
- akta.pro rank
Pappas Ventures industry classification
Industry- Product category
- Life Sciences Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
Keywords
Where Pappas Ventures is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Pappas Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Distribution channels1 record
Marketing channels3 records
Pappas Ventures product offering
Product offeringCore offering
Pappas Ventures is a life sciences venture capital firm that invests capital, provides strategic guidance, and offers operational expertise to early-stage and growth-stage biotechnology, pharmaceutical, and healthcare companies. The firm manages multiple specialized funds — including Chiesi Ventures Fund, Asia Innovation Ventures, AgTech Initiatives, and the Wake Forest Innovation Catalyst Fund — to deploy capital across respiratory/rare disease, cross-border innovation, agricultural technology, and university-sourced translational medicine opportunities.
Product overview
Pappas Ventures operates as a life science venture capital firm offering a unified investment platform with multiple specialized funds and initiatives. The core offering is venture investment services through Pappas Ventures, supplemented by specialized funds including the Chiesi Ventures Fund (focused on respiratory and rare diseases), Asia Innovation Ventures (cross-border opportunities), and AgTech Innovations (agricultural technology). The firm also provides translational medicine support through the Wake Forest Innovation Catalyst Fund partnership. The portfolio spans more than 100 companies across the United States, Canada, and Asia.
Differentiator
Problem solved
Functional benefit
Products and services
- Pappas Ventures Venture capital investment services providing funding and strategic guidance to innovative life science companies developing next-generation biotechnology and healthcare products. Targets founders and management teams across the range of human disease.
- Chiesi Ventures Fund A specialized venture fund managed in partnership with Chiesi Pharmaceuticals, focused on investments in companies developing therapeutics for respiratory, rare disease, and specialty care indications. Available to institutional and strategic investors seeking targeted exposure to these therapeutic areas.
- Asia Innovation Ventures Specialized investment vehicle focused on cross-border innovation opportunities between Asian and North American life science markets. Provides capital and strategic guidance to portfolio companies operating across these regions.
- AgTech Innovations Investment initiative supporting innovative companies in the agricultural technology sector. Provides venture capital to agtech companies developing new products and technologies for agriculture.
- Wake Forest Innovation Catalyst Fund Translational medicine program operated in partnership with Wake Forest University that supports early-stage research commercialization from the university into investable life science companies. Provides funding, development support, and a commercialization pathway for university-sourced technologies.
Quantifiable outcome
- Products used to treat tens of thousands of patients worldwide
- +1 more outcomes
Companies that use Pappas Ventures
Customer profileSegments2 records
Ideal customer profiles2 records
Pappas Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Pappas Ventures partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor.
- NVCA (National Venture Capital Association)minorMembership in leading venture capital industry association
- BIOminorMembership in biotechnology industry organization
- NC Biotech (North Carolina Biotechnology Center)minorMembership in regional biotechnology organization supporting life science ecosystem in North Carolina
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Pappas Ventures competitors and assessment
Company assessmentDirect peers
- ARCH Venture Partners: Early-stage life sciences and technology venture firm with deep biotech expertise and multiple funds. Comparable to Pappas as a thesis-driven life sciences VC backing breakthrough therapeutics from inception.
- OrbiMed: One of the largest dedicated healthcare and life sciences venture capital firms, investing across stages from seed to public companies. Directly comparable as a specialized life sciences VC with a multi-fund platform serving institutional LPs.
- Atlas Venture: Early-stage life sciences venture capital firm that builds biotech companies from inception. Directly comparable as a focused life sciences VC with an active, multi-fund platform targeting founders.
- 5AM Ventures: Life sciences-focused venture capital firm investing in early-stage biotech across therapeutics and platforms. Comparable to Pappas as a similarly-sized, science-driven life sciences VC with multi-fund structure.
- Frazier Healthcare Partners: Healthcare-focused venture and growth capital firm with dedicated life sciences practice. Comparable to Pappas as a long-established healthcare VC operating multiple funds across therapeutic areas and stages.
- Versant Ventures: Healthcare-focused venture capital firm with dedicated biotech and medical device teams. Comparable to Pappas as a multi-fund life sciences investor backing therapeutic companies from early to late stages.
- Third Rock Ventures: Biotech-focused venture firm that builds and launches life sciences companies around breakthrough science. Comparable to Pappas as a translational-medicine-oriented life sciences VC creating companies around academic and clinical innovation.
Broad incumbents
- New Enterprise Associates (NEA): Large multi-stage venture capital firm with a dedicated healthcare practice. Comparable to Pappas as a healthcare-focused investor, though NEA operates at significantly greater scale across technology and healthcare.
- SR One (GSK): Corporate venture capital arm of GlaxoSmithKline investing in biotech and life sciences. Comparable to Pappas via the Chiesi Ventures Fund model — a corporate-affiliated life sciences investment vehicle with strategic LP alignment.
- Deerfield Management: Healthcare-focused investment firm across venture, growth, and public equities. Comparable to Pappas as a diversified life sciences investment platform, though Deerfield operates with substantially larger AUM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Pappas Ventures social profiles
Digital presencePappas Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pappas Ventures leadership team
Management profileNumber of profiles
Profiles1 record
Pappas Ventures subsidiaries and ownership
Company hierarchySubsidiaries4 records
Pappas Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pappas Ventures M&A and investment
M&A and investmentM&A
Investments54 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pappas Ventures
What does Pappas Ventures do?
Pappas Ventures is a life sciences venture capital firm that invests capital, provides strategic guidance, and offers operational expertise to early-stage and growth-stage biotechnology, pharmaceutical, and healthcare companies. The firm manages multiple specialized funds — including Chiesi Ventures Fund, Asia Innovation Ventures, AgTech Initiatives, and the Wake Forest Innovation Catalyst Fund — to deploy capital across respiratory/rare disease, cross-border innovation, agricultural technology, and university-sourced translational medicine opportunities.
Is Pappas Ventures a public or private company?
Pappas Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Pappas Ventures founded?
Pappas Ventures was founded in 1994. It employs 11 to 50 people.
Where is Pappas Ventures based?
Pappas Ventures is headquartered in Durham, United States, in the North America region.
Who are Pappas Ventures's main competitors?
Direct peers on record are ARCH Venture Partners, OrbiMed, Atlas Venture, 5AM Ventures, Frazier Healthcare Partners, Versant Ventures and Third Rock Ventures. Broad incumbents are New Enterprise Associates (NEA), SR One (GSK) and Deerfield Management.
Does Pappas Ventures have an API?
No public API is recorded for Pappas Ventures.
What industry is Pappas Ventures in?
Pappas Ventures's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 523940 and its SIC code is 6282.